

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q67718

Kozo AOKI, et al.

Appln. No.: 10/019,249

Group Art Unit: 1625

Confirmation No.: 1284

Examiner: Patricia L. MORRIS

Filed: June 05, 2002

BENZIMIDAZOLE COMPOUNDS AND MEDICAMENTS COMPRISING THE SAME

EXCESS CLAIM FEE PAYMENT LETTER

Commissioner for Patents Washington, D.C. 20231

Sir:

For:

An Amendment Under 37 C.F.R. § 1.111 is attached hereto for concurrent filing in the above-identified application. The resulting excess claim fee has been calculated as shown below:

	After Amendment		Highest No. Previously Paid For							
All Claims	27	-	22	=	5	Σ	ζ	\$18.00	=	\$90.00
Independent	4	-	3		1	Σ	ζ	\$84.00	=	\$84.00
•					TOTAL				=	\$174.00

The azstatutory fee of \$174.00 is to be charged to Deposit Account No. 19-4880. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this letter is enclosed.

SUGHRUE MION, PLLC

2100 Pennsylvania Avenue, N.W.

Washington, D.C. 20037-3213 Telephone: (202) 293-7060

Facsimile: (202) 293-7860 Date: October 7, 2002 Respectfully submitted,

Jennifer M. Hayes

Registration No. 40,641